Amgen boss makes a prime breakup target

October 22, 2014

Former Morgan Stanley banker Robert Bradway runs the $109 bln biotech being eyed by activist Dan Loeb. Splitting into a cash cow and a growth arm comes up often in the industry but rarely happens. In Amgen’s case, its drug focus and the CEO’s background give the idea a chance.

Amgen investors gain from investment banker CEO

By Rob Cox
September 5, 2013

The biotech led by Bob Bradway, formerly of Morgan Stanley, made mincemeat of the value arguments put up by Onyx and its advisers, raising its offer only 4 pct to clinch a $10.4 bln deal last week. An M&A banker at the helm can work – when it’s negotiating prowess that matters.